Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2009

Open Access 01-12-2009 | Research

Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract

Authors: George Miller, Nicholas D Socci, Deepti Dhall, Michael D'Angelica, Ronald P DeMatteo, Peter J Allen, Bhuvanesh Singh, Yuman Fong, Leslie H Blumgart, David S Klimstra, William R Jarnagin

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2009

Login to get access

Abstract

Background

The pathogenesis of biliary cancers is ill-defined. This study investigates changes in gene expression and copy number in biliary cancers and correlates these changes with anatomical site of origin, histopathology and outcome.

Methods

We performed gene expression and CGH analysis on 34 biliary tract cancer specimens. Results were confirmed by RT-PCR. Clinical-pathologic correlation was made using functional over-representation analysis of the top 100 mutations associated with each variable.

Results

There were 545 genes with altered expression in extrahepatic cholangiocarcinoma, 2,354 in intrahepatic cholangiocarcinoma, and 1,281 in gallbladder cancer. Unsupervised hierarchical clustering analysis indicated there was no difference in the global gene expression patterns between each biliary cancer subgroup. CGH analysis revealed that short segments of chromosomes 1p, 3p, 6q, 8p, 9p, and 14q were commonly deleted across all cancer subtypes. Commonly amplified regions included segments of 1q, 3q, 5p, 7p, 7q, 8q, and 20q. Over-representation analysis revealed an association between altered expression of functional gene groupings and pathologic features.

Conclusion

This study defined regions of the genome associated with changes in DNA copy number and gene expression in specific subtypes of biliary cancers. The findings have implications for identification of therapeutic targets, screening, and prognostication.
Appendix
Available only for authorised users
Literature
1.
go back to reference Miller G, Jarnagin WR: Gallbladder carcinoma. 2008, 34: 306-312. Miller G, Jarnagin WR: Gallbladder carcinoma. 2008, 34: 306-312.
2.
go back to reference Randi G, Franceschi S, La VC: Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006, 118 (7): 1591-602. 10.1002/ijc.21683.CrossRef Randi G, Franceschi S, La VC: Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006, 118 (7): 1591-602. 10.1002/ijc.21683.CrossRef
3.
go back to reference Serra I, Calvo A, Baez S, Yamamoto M, Endoh K, Aranda W: Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer. 1996, 78 (7): 1515-7. 10.1002/(SICI)1097-0142(19961001)78:7<1515::AID-CNCR21>3.0.CO;2-1.CrossRef Serra I, Calvo A, Baez S, Yamamoto M, Endoh K, Aranda W: Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer. 1996, 78 (7): 1515-7. 10.1002/(SICI)1097-0142(19961001)78:7<1515::AID-CNCR21>3.0.CO;2-1.CrossRef
4.
go back to reference Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BAM, Klimstra D, Blumgart LH: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001, 234 (4): 507-17. 10.1097/00000658-200110000-00010.CrossRef Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BAM, Klimstra D, Blumgart LH: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001, 234 (4): 507-17. 10.1097/00000658-200110000-00010.CrossRef
5.
go back to reference Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, Wagman R, Blumgart LH, Fong Y: Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003, 98 (8): 1689-700. 10.1002/cncr.11699.CrossRef Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, Wagman R, Blumgart LH, Fong Y: Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003, 98 (8): 1689-700. 10.1002/cncr.11699.CrossRef
6.
go back to reference Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH: Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001, 193 (4): 384-91. 10.1016/S1072-7515(01)01016-X.CrossRef Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH: Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001, 193 (4): 384-91. 10.1016/S1072-7515(01)01016-X.CrossRef
7.
go back to reference Kuroki T, Tajima Y, Matsuo K, Kanematsu T: Genetic alterations in gallbladder carcinoma. Surg Today. 2005, 35 (2): 101-5. 10.1007/s00595-004-2906-2.CrossRef Kuroki T, Tajima Y, Matsuo K, Kanematsu T: Genetic alterations in gallbladder carcinoma. Surg Today. 2005, 35 (2): 101-5. 10.1007/s00595-004-2906-2.CrossRef
8.
go back to reference Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, Shen MC, Deng J, Hsing AW: K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res. 2002, 8 (10): 3156-63. Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, Shen MC, Deng J, Hsing AW: K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res. 2002, 8 (10): 3156-63.
9.
go back to reference Benckert C, Jonas S, Cramer T, Von MZ, Schafer G, Peters M, Wagner K, Radke C, Wiedenmann B, Neuhaus P, Höcker M, Rosewicz S: Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003, 63 (5): 1083-92. Benckert C, Jonas S, Cramer T, Von MZ, Schafer G, Peters M, Wagner K, Radke C, Wiedenmann B, Neuhaus P, Höcker M, Rosewicz S: Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003, 63 (5): 1083-92.
10.
go back to reference Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE: ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002, 36 (2): 439-50. 10.1053/jhep.2002.34435.CrossRef Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE: ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002, 36 (2): 439-50. 10.1053/jhep.2002.34435.CrossRef
11.
go back to reference Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ: Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005, 42 (6): 1329-38. 10.1002/hep.20966.CrossRef Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ: Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005, 42 (6): 1329-38. 10.1002/hep.20966.CrossRef
12.
go back to reference Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ: Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005, 128 (7): 2054-65. 10.1053/j.gastro.2005.03.010.CrossRef Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ: Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005, 128 (7): 2054-65. 10.1053/j.gastro.2005.03.010.CrossRef
13.
go back to reference Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol. 2006, 24 (7): 1152-60. 10.1200/JCO.2005.04.6631.CrossRef Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol. 2006, 24 (7): 1152-60. 10.1200/JCO.2005.04.6631.CrossRef
14.
go back to reference Olshen AB, Venkatraman ES, Lucito R, Wigler M: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004, 5 (4): 557-72. 10.1093/biostatistics/kxh008.CrossRef Olshen AB, Venkatraman ES, Lucito R, Wigler M: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004, 5 (4): 557-72. 10.1093/biostatistics/kxh008.CrossRef
15.
go back to reference Kang YK, Kim WH, Jang JJ: Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol. 2002, 33 (9): 877-83. 10.1053/hupa.2002.127444.CrossRef Kang YK, Kim WH, Jang JJ: Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol. 2002, 33 (9): 877-83. 10.1053/hupa.2002.127444.CrossRef
16.
go back to reference Kim YT, Kim J, Jang YH, Lee WJ, Ryu JK, Park YK, Kim SW, Kim WH, Yoon YB, Kim CY: Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett. 2001, 169 (1): 59-68. 10.1016/S0304-3835(01)00562-6.CrossRef Kim YT, Kim J, Jang YH, Lee WJ, Ryu JK, Park YK, Kim SW, Kim WH, Yoon YB, Kim CY: Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett. 2001, 169 (1): 59-68. 10.1016/S0304-3835(01)00562-6.CrossRef
17.
go back to reference Chang HJ, Kim SW, Kim YT, Kim WH: Loss of heterozygosity in dysplasia and carcinoma of the gallbladder. Mod Pathol. 1999, 12 (8): 763-9. Chang HJ, Kim SW, Kim YT, Kim WH: Loss of heterozygosity in dysplasia and carcinoma of the gallbladder. Mod Pathol. 1999, 12 (8): 763-9.
18.
go back to reference Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A: Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005, 206 (3): 356-65. 10.1002/path.1779.CrossRef Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A: Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005, 206 (3): 356-65. 10.1002/path.1779.CrossRef
19.
go back to reference Roa JC, Roa I, Correa P, Vo Q, Araya JC, Villaseca M, Guzmán P, Schneider BG: Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. J Gastroenterol. 2005, 40 (1): 79-86. 10.1007/s00535-004-1497-4.CrossRef Roa JC, Roa I, Correa P, Vo Q, Araya JC, Villaseca M, Guzmán P, Schneider BG: Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. J Gastroenterol. 2005, 40 (1): 79-86. 10.1007/s00535-004-1497-4.CrossRef
20.
go back to reference Wang TL, Diaz LA, Romans K, Bardelli A, Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih IeM, Iacobuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE: Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA. 2004, 101 (9): 3089-94. 10.1073/pnas.0308716101.CrossRef Wang TL, Diaz LA, Romans K, Bardelli A, Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih IeM, Iacobuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE: Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA. 2004, 101 (9): 3089-94. 10.1073/pnas.0308716101.CrossRef
21.
go back to reference Hoeller D, Hecker CM, Dikic I: Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006, 6 (10): 776-88. 10.1038/nrc1994.CrossRef Hoeller D, Hecker CM, Dikic I: Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006, 6 (10): 776-88. 10.1038/nrc1994.CrossRef
22.
go back to reference Dikic I, Crosetto N, Calatroni S, Bernasconi P: Targeting ubiquitin in cancers. Eur J Cancer. 2006, 42 (18): 3095-102. 10.1016/j.ejca.2006.05.041.CrossRef Dikic I, Crosetto N, Calatroni S, Bernasconi P: Targeting ubiquitin in cancers. Eur J Cancer. 2006, 42 (18): 3095-102. 10.1016/j.ejca.2006.05.041.CrossRef
23.
go back to reference Vaclavicek A, Bermejo JL, Schmutzler RK, Sutter C, Wappenschmidt B, Meindl A, Kiechle M, Arnold N, Weber BH, Niederacher D, Burwinkel B, Bartram CR, Hemminki K, Försti A: Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr Relat Cancer. 2007, 14 (2): 267-77. 10.1677/ERC-06-0077.CrossRef Vaclavicek A, Bermejo JL, Schmutzler RK, Sutter C, Wappenschmidt B, Meindl A, Kiechle M, Arnold N, Weber BH, Niederacher D, Burwinkel B, Bartram CR, Hemminki K, Försti A: Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr Relat Cancer. 2007, 14 (2): 267-77. 10.1677/ERC-06-0077.CrossRef
24.
go back to reference Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, Edwards J: Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer. 2007, 97 (3): 378-83. 10.1038/sj.bjc.6603871.CrossRef Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, Edwards J: Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer. 2007, 97 (3): 378-83. 10.1038/sj.bjc.6603871.CrossRef
25.
go back to reference Dowlati A, Nethery D, Kern JA: Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther. 2004, 3 (4): 459-63. Dowlati A, Nethery D, Kern JA: Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther. 2004, 3 (4): 459-63.
Metadata
Title
Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract
Authors
George Miller
Nicholas D Socci
Deepti Dhall
Michael D'Angelica
Ronald P DeMatteo
Peter J Allen
Bhuvanesh Singh
Yuman Fong
Leslie H Blumgart
David S Klimstra
William R Jarnagin
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2009
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-28-62

Other articles of this Issue 1/2009

Journal of Experimental & Clinical Cancer Research 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine